STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Not yet recruiting
- Acute Myeloid Leukemia
- Relapsed Adult AML
- Lintuzumab-Ac225
- +2 more
- (no location specified)
2022-02-22
Feb 22, 2022M
Recruiting
- MDS
- AML
- Bronx, New YorkMontefiore Medical Center
2022-03-24
Mar 24, 2022Z
Active, not recruiting
- AML
- Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
2022-02-21
Feb 21, 2022U
Active, not recruiting
- Acute Myeloid Leukemia
- Baltimore, MarylandUniversity of Maryland Greenebaum Comprehensive Cancer Center
2021-10-05
Oct 5, 2021M
Terminated
- AML Including AML de Novo and AML Secondary to MDS
- DLBCL
- Birabresib Dose 20 mg
- (no location specified)
2021-09-29
Sep 29, 2021H
Recruiting
- AML
- Hyperleukocytosis
- Vinblastine
- Hydroxyurea capsules
- Monterrey, Nuevo Leon, MexicoHopsital Universitario Dr. Jose E. Gonzalez, Centro Universitari
2021-10-09
Oct 9, 2021C
Not yet recruiting
- AML
- Gemtuzumab ozogamicine - Cytarabine - Gilteritinib
- (no location specified)
2022-01-05
Jan 5, 2022H
Terminated
- AML
- AML, Adult
- Indianapolis, IndianaIndiana University Melvin and Bren Simon Cancer Center
2022-03-15
Mar 15, 2022A
Recruiting
- Acute Myeloid Leukemia
- Relapsed Adult AML
- Lintuzumab-Ac225
- +2 more
- Los Angeles, California
- +4 more
2022-02-22
Feb 22, 2022M
Not yet recruiting
- AML
- Acute Myelogenous Leukemia
- Scaling and Root Planing
- (no location specified)
2021-08-03
Aug 3, 2021M
Not yet recruiting
- AML
- MDS
- Vibecotamab
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-03-08
Mar 8, 2022C
Not yet recruiting
- Myeloid Leukemia
- Interviews
- (no location specified)
2022-03-25
Mar 25, 2022B
Recruiting
- Acute Myeloid Leukemia
- NK cell infusions
- Minsk, Minsk Region, BelarusBelarussian Research Center for Pediatric Oncology, Hematology a
2022-02-28
Feb 28, 2022U
Recruiting
- AML, Adult
- Berne, SwitzerlandDepartement of Medical Oncology, University Hospital Berne
2022-01-27
Jan 27, 2022U
Recruiting
- AML
- Acute Myeloid Leukemia
- Charlottesville, VirginiaUniversity of Virginia
2022-03-09
Mar 9, 2022C
Not yet recruiting
- Acute Myeloid Leukemia in Remission
- Prospective determination of the clinical utility of measurable residual disease (MRD) testing
- (no location specified)
2022-01-25
Jan 25, 2022A
Withdrawn
- AML
- APVO436
- (no location specified)
2021-11-29
Nov 29, 2021H
Recruiting
- Myeloid Malignancy
- Detroit, MichiganHenry ford hospital
2021-12-23
Dec 23, 2021B
Active, not recruiting
- Acute Myelogenous Leukemia
- AML
- DC AML Vaccine
- Boston, MassachusettsBeth Israel Deaconess Medical Center
2022-01-25
Jan 25, 2022S
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- San Francisco, CaliforniaStanford University
2022-02-07
Feb 7, 2022W
Recruiting
- Whole Genome Sequencing
- +2 more
- ChromoSeq
- Saint Louis, MissouriWashington University School of Medicine
2022-04-06
Apr 6, 2022H
Recruiting
- AML
- CAR-γδT
- Yanda, Hebei, ChinaHebei yanda Ludaopei Hospital
2021-03-11
Mar 11, 2021W
Withdrawn
- Relapsed Acute Myeloid Leukemia
- +2 more
- Cytokine-induced memory-like NK cells
- +4 more
- (no location specified)
2022-02-23
Feb 23, 2022D
Recruiting
- Acute Myelogenous Leukemia
- decitabine
- DC/AML fusion cells
- Boston, Massachusetts
- +1 more
2021-11-15
Nov 15, 2021H
Recruiting
- Myelodysplastic Syndromes
- Secondary Acute Myeloid Leukemia
- CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
- Standard of Care Chemotherapy
- Tampa, FloridaMoffitt Cancer Center
2022-01-26
Jan 26, 2022